Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: November Update

Performance overview
Value at beginning of month: $120,535.66
Value at end of month: $114,071.00
Month over month change: -5.36%
Total CAGR: 15.33%

Related indices, monthly change
NASDAQ: +2.18%
IVV (iShares Core S&P 500): +2.64%
IBB (iShares NASDAQ Biotechnology Index): +0.31%
MXI (iShares Global Materials): +0.06%
VEGI (iShares MSCI Global Agriculture Producers): -0.28%
ICLN (iShares Clean Energy): -5.05%

Individual performances


Calyxt and Intrexon showed modest losses after disappointing Q3 results, which dragged the index to a negative performance for the month. Few of the companies had positive results, and Amyris led the pack up 15%. 

Changes made to index

None, you can view the index here.

Allocation as of December 1, 2017


Synthetic biology venture investment in 2017

Calvin Schmidt Synthetic Biology Index: October Update